Search Results - Victoria Rollason

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics by Camille Lenoir, Amine Niederer, Victoria Rollason, Jules Alexandre Desmeules, Youssef Daali, Caroline Flora Samer

    Get full text
    Article


  2. 2

    Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients by Nadia Exquis, Benjamin Dionisi, Caroline Flora Samer, Victoria Rollason, François Curtin, Dina Zekry, Christophe Graf, Virgnie Prendki, Kuntheavy Ing Lorenzini

    Published in Viruses (2024-05-01)
    Get full text
    Article


  3. 3

    Hypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report. by Ulrika Marking, Margriet den Boer, Asish Kumar Das, Elshafie Mohamed Ahmed, Victoria Rollason, Be-Nazir Ahmed, Robert N Davidson, Koert Ritmeijer

    Published in PLoS Neglected Tropical Diseases (2014-06-01)
    Get full text
    Article


  4. 4

    Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study by Frédéric Gaspar, Jean Terrier, Samantha Favre, Pauline Gosselin, Pierre Fontana, Youssef Daali, Camille Lenoir, Caroline Flora Samer, Victoria Rollason, Jean‐Luc Reny, Chantal Csajka, Monia Guidi

    Get full text
    Article


  5. 5

    Apixaban and rivaroxaban's physiologically‐based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side by Jean Terrier, Frédéric Gaspar, Pauline Gosselin, Olivier Raboud, Camille Lenoir, Victoria Rollason, Chantal Csajka, Caroline Samer, Pierre Fontana, Youssef Daali, Jean‐Luc Reny, for the OptimAT study group

    Get full text
    Article


  6. 6

    Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for M... by Robert Barouki, Joël Ankri, Patrick Maison, Christiane Druml, Valérie Sautou, Eric Bellissant, Laëtitia Belgodère, Dominique Pougheon Bertrand, Marie Christine Jaulent, Vololona Rabeharisoa, Walter Janssens, Victoria Rollason, Janine Barbot, Jean Paul Vernant, Wahiba Oualikene Gonin, Henri Bastos, Éric Ezan, Didier Houssin, Maria Emilia Monteiro, Dominique Pougheon Bertrand, Marie-Christine Jaulent, Jean-Paul Vernant

    Published in BMJ Global Health (2023-05-01)
    Get full text
    Article


  7. 7

    Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines... by Wahiba Oualikene-Gonin, Valérie Sautou, Eric Ezan, Henri Bastos, Eric Bellissant, Laëtitia Belgodère, Patrick Maison, Patrick Maison, Patrick Maison, Joël Ankri, The Scientific Advisory Board of the ANSM, Joël Ankri, Janine Barbot, Robert Barouki, Henri Bastos, Éric Bellissant, Christiane Druml, Éric Ezan, Didier Houssin, Walter Janssens, Marie-Christine Jaulent, Maria Emilia Monteiro, Dominique Pougheon, Vololona Rabeharisoa, Victoria Rollason, Valérie Sautou, Jean-Paul Vernant

    Published in Frontiers in Public Health (2023-03-01)
    Get full text
    Article


Search Tools: